Oral anticoagulant treatment: friend or foe in cardiovascular disease?
about
The health benefits of vitamin KVascular calcification: pathobiology of a multifaceted diseaseCholesterol in vascular and valvular calcificationMedial vascular calcification revisited: review and perspectivesMatrix gla protein (MGP): an overexpressed and migration-promoting mesenchymal component in glioblastoma.The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report.Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.Association of warfarin use with valvular and vascular calcification: a review.Rapidly progressive severe vascular calcification sparing the kidney allograft following warfarin initiation.Molecular mechanisms mediating vascular calcification: role of matrix Gla protein.Arterial microcalcifications in the breast mimicking malignancyWarfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticumVitamin K status and vascular calcification: evidence from observational and clinical studies.The role of vitamin K in soft-tissue calcification.Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcificationA cardiovascular phenotype in warfarin-resistant Vkorc1 mutant ratsVitamin K-dependent proteins, warfarin, and vascular calcificationArterial calcifications.Intake of dietary phylloquinone and menaquinones and risk of stroke.Correlates of valvular ossification in patients with aortic valve stenosis.Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship.Oral anticoagulant-associated intracerebral hemorrhage.Osteoporosis--a risk factor for cardiovascular disease?A four-season molecule: osteocalcin. Updates in its physiological roles.CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis.Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) Retrospective Analysis.Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy.Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1.Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index.Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment.Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population.Therapeutic warfarin use and the extrahepatic functions of vitamin K-dependent proteins.[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].Prevalence and determinants of coronary and aortic calcifications assessed by chest CT in renal transplant recipients.The Association Between Long-Term Acenocoumarol Treatment and Vitamin D Deficiency.Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population-Based Gutenberg Health StudyMissense mutation of VKORC1 leads to medial arterial calcification in rats
P2860
Q26782816-FFF18140-C916-4876-9949-E9E5A1DE920EQ28282418-17119636-425E-4CF0-AA92-C7200BD03555Q28361780-917E6BF4-F999-43F3-971A-5DBF770F3A17Q30409314-6944932C-DBEF-4BD4-81E1-F806E62A4066Q33497632-615A9DDE-6A83-4B6B-B1DB-D9D1B72ADB3CQ33769989-646820DB-C644-40C8-BCE6-F18850ED8CB0Q34033497-56D92585-B533-4B41-A4EA-8D024D9BBC68Q34162996-1D5AF889-E292-4C13-BE20-A047B6D40FD9Q34348892-DCF77376-547B-49EB-9829-D3290703335CQ34570670-27312149-7AF9-4751-A416-2DDDA67390A1Q35952810-16638D35-47F1-419C-91C2-658D3EC02A7CQ36750182-0F6E9BB7-CB59-4C11-8F9A-B180D44A801AQ36828717-C1303B52-3340-40B3-B13C-7F8952C6B29CQ36828721-8585B874-A593-4887-8F8B-C9C5C4AA8088Q36925289-B393BEDD-750A-4FFB-950F-B2BD3A219621Q37088955-0E4726A1-B82E-4299-8DC1-B92E1DC79962Q37170124-E3EC2010-8812-4FB2-942C-118B6D371EDAQ37293900-2690890D-4804-4954-A126-92EF8206C9BFQ37457640-C3A3DDE6-B3BF-4D7F-9704-BB189A97BBDCQ37700421-DA608D33-AE21-4838-A198-07181BEDC78CQ37810737-FFDD9359-1F3F-49EF-A106-DF311E5DD0BEQ37900185-3E03246B-1A77-4CED-84D1-7601880A0C1FQ38034388-B143953C-2221-4572-B46F-2175A28E59CFQ38243461-675AC962-B437-4320-98A5-AFBFED8E6669Q42951347-6CE642AF-7A2B-4009-939B-4303C22145AAQ43199667-B83EB062-1A2D-4897-BD1C-A687DA0B250EQ43216808-B2D31F54-3037-4E11-926F-DE3D86AC35F4Q43799862-45D6B588-E8B5-422D-B0DD-0CD0B960D1C4Q45937484-2AC16D3D-5EEC-4257-91CB-4C1811BE68E6Q46071755-2B26861B-90B1-49E7-B18F-0DA2EBC5187FQ46279181-DA145AE9-22F7-407C-B7E2-87E671A18B65Q47404990-8A271851-746E-4227-ABB4-A47873598323Q47676686-AADAEDC9-2B49-494C-A465-B304777F707AQ48209070-565E1048-8452-4B38-92F9-734E0E6A0DEBQ52840065-89ECD17C-B609-48E8-99A8-D4C1924AA965Q53481376-111084D1-204B-4E41-9AEC-1C55EC4C0918Q55455498-607A75E4-A500-479F-8A93-AB238E466625Q58127461-42C70460-5459-46D6-BCF7-8E9CE55E193CQ58743826-54BC1B5A-141C-4910-8863-E545DD25E273
P2860
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@ast
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@en
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@nl
type
label
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@ast
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@en
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@nl
prefLabel
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@ast
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@en
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@nl
P2093
P1433
P1476
Oral anticoagulant treatment: friend or foe in cardiovascular disease?
@en
P2093
Burkhard Bültmann
Hermann Aebert
Jan Janzen
Leon J Schurgers
P304
P356
10.1182/BLOOD-2004-04-1277
P407
P50
P577
2004-07-20T00:00:00Z